Ben Tran

1. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
   2026/07/27 by Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi +13 · 1 voice
   Immunology and Microbiology · Medicine · #Bladder and Urothelial Cancer Treatments #Immune responses and vaccinations #Urinary and Genital Oncology Studies